| Expression pattern: |
UP |
| Associated gene: |
NFIX, SNTB2, RAF1 |
| Associated microRNA: |
miR-137, miR-7 |
| Biological function: |
boosts cancer development; manipulates cell cycle and apoptosis in CLL cells |
| Molecular mechanism: |
interaction network via miRNAs (miR-137; miR-193 family; miR-7) with mediators (NFIX, SNTB2, RAF1) to influence cell cycle, apoptosis, and PDGF signaling |
| Biological pathway or process: |
cell cycle (other); apoptosis (inhibits); other pathway/process (other) |
| Detected method: |
S
|
| Validation methods: |
RNA-seq; Bioinformatics Analysis; ROC Analysis; Survival Analysis; Cohort Study |
| Clinical significance: |
Diagnostic biomarker (AUC reported) and prognostic association with 5-year OS (high level associated with worse OS). |
| Description: |
circMDM2 is increased in CLL and included in a diagnostic/prognostic circRNA panel. Network analysis links circMDM2 to miRNA-mediated interactions (miR-137/miR-7 and miR-193 family) with targets such as NFIX, SNTB2 and RAF1, affecting cell cycle/apoptosis programs and contributing to CLL progression; higher expression correlates with worse OS in validation cohorts. |
| Confidence score: |
0.5121 |